Erratum: Selinexor Plus Ruxolitinib in Janus Kinase Inhibitor–Naïve Myelofibrosis: Phase III SENTRY Trial

Prithviraj Bose

5University of Texas MD Anderson Cancer Center, Houston, United States

Haris Ali

Haifa Kathrin Al-Ali

3Krukenberg Cancer-Center, University Hospital Halle (Saale), Halle, Germany

Valentin Garcia-Gutierrez

Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain

Sebastian Grosicki

Department of Cancer Prevention, Medical University of Silesia, Katowice, Poland

Zhanet Grudeva-Popova

8Medical University of Plovdiv, Plovdiv, Bulgaria

Claire Harrison

11Department of Haematology, Guy’s and St Thomas’ National Health Service Foundation Trust, London, United Kingdom

Junshik Hong

Hsin-An Hou

10National Taiwan University Hospital, Taipei, Taiwan

Michal Kwiatek

2AIDPORT Clinical Trials Hospital, Skorzewo, Poland

Michael Loschi

12Centre Hospitalier Universitaire de Nice, Nice, France

Francesco Passamonti

University of Milan, Milan

Nikolai Podoltsev

15Yale University, New Haven, United States

Raajit Rampal

15Memorial Sloan Kettering Cancer Center, New York, United States

Srinivas Tantravahi

16Huntsman Cancer Institute, Salt Lake City, United States

Laura Gabriela Urian

6Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Romania

Yi Chai

Pietro Taverna

18Karyopharm Therapeutics, Newton, United States

Tomer Mark

4Karyopharm Therapeutics, Newton, United States

Amama Sadiq

Karyopharm Therapeutics, Newton, MA

Reshma Rangwala

Karyopharm Therapeutics, Newton, MA

Pankit Vachhani

25University of Alabama at Birmingham Cancer Center, Birmingham, United States

John Mascarenhas

4Icahn School of Medicine at Mount Sinai, New York, United States